

2019 Future of Mild Cognitive Impairment (MCI) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/274C794BF10EN.html>

Date: February 2019

Pages: 65

Price: US\$ 2,199.00 (Single User License)

ID: 274C794BF10EN

Abstracts

The global demand for Mild Cognitive Impairment (MCI) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Mild Cognitive Impairment (MCI) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Mild Cognitive Impairment (MCI) pipeline companies from advancing their products into Phase 3 or Phase 4.

Mild Cognitive Impairment (MCI) Report Description-

The 2019 pipeline study on Mild Cognitive Impairment (MCI) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Mild Cognitive Impairment (MCI) pipeline compounds.

The Mild Cognitive Impairment (MCI) pipeline guide presents information on all active drugs currently being developed for Mild Cognitive Impairment (MCI). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Mild Cognitive Impairment (MCI) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Mild Cognitive Impairment (MCI) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Mild Cognitive Impairment (MCI) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Mild Cognitive Impairment (MCI) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Mild Cognitive Impairment (MCI) pipeline report includes-

An overview of Mild Cognitive Impairment (MCI) disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Mild Cognitive Impairment (MCI) pipeline

Company wise list of Mild Cognitive Impairment (MCI) pipeline

Mechanism of Action wise Mild Cognitive Impairment (MCI) pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Mild Cognitive Impairment (MCI) pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Mild Cognitive Impairment (MCI) pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Mild Cognitive Impairment (MCI) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Mild Cognitive Impairment (MCI) Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Mild Cognitive Impairment (MCI) pipeline, H1- 2019
- 3.5 Mechanism of Action wise Mild Cognitive Impairment (MCI) Pipeline Candidates

4 ABBVIE INC MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 4.1 AbbVie Inc Business Profile
- 4.2 AbbVie Inc Mild Cognitive Impairment (MCI) Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity
 - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 AGENEBIO INC MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 5.1 AgeneBio Inc Business Profile
- 5.2 AgeneBio Inc Mild Cognitive Impairment (MCI) Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 AVRAHAM PHARMACEUTICALS LTD MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 6.1 Avraham Pharmaceuticals Ltd Business Profile
- 6.2 Avraham Pharmaceuticals Ltd Mild Cognitive Impairment (MCI) Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 BIOGEN INC MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 7.1 Biogen Inc Business Profile
- 7.2 Biogen Inc Mild Cognitive Impairment (MCI) Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 CERESPIR INC MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 8.1 CereSpir Inc Business Profile
- 8.2 CereSpir Inc Mild Cognitive Impairment (MCI) Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 EISAI CO LTD MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 9.1 Eisai Co Ltd Business Profile
- 9.2 Eisai Co Ltd Mild Cognitive Impairment (MCI) Drug Details

9.3 Drug Snapshot

9.3.1 Originator

9.3.2 Collaborator/Co-Developer

9.3.3 Route of Administration

9.3.4 Orphan Drug/Fast Track/Special Designation

9.3.5 Geography

9.3.6 Type of Molecular Entity

9.3.7 Current Status

9.4 Drug Overview

9.5 Drug Mechanism of Action

9.6 Clinical/Pre-clinical Trial Details

9.7 Latest Drug Developments

10 ELI LILLY AND CO MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

10.1 Eli Lilly and Co Business Profile

10.2 Eli Lilly and Co Mild Cognitive Impairment (MCI) Drug Details

10.3 Drug Snapshot

10.3.1 Originator

10.3.2 Collaborator/Co-Developer

10.3.3 Route of Administration

10.3.4 Orphan Drug/Fast Track/Special Designation

10.3.5 Geography

10.3.6 Type of Molecular Entity

10.3.7 Current Status

10.4 Drug Overview

10.5 Drug Mechanism of Action

10.6 Clinical/Pre-clinical Trial Details

10.7 Latest Drug Developments

11 INTELGENX CORP MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

11.1 IntelGenx Corp Business Profile

11.2 IntelGenx Corp Mild Cognitive Impairment (MCI) Drug Details

11.3 Drug Snapshot

11.3.1 Originator

11.3.2 Collaborator/Co-Developer

11.3.3 Route of Administration

11.3.4 Orphan Drug/Fast Track/Special Designation

- 11.3.5 Geography
- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 NEURON BIOPHARMA SA MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 12.1 Neuron Biopharma SA Business Profile
- 12.2 Neuron Biopharma SA Mild Cognitive Impairment (MCI) Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 OCTAPHARMA AG MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 13.1 Octapharma AG Business Profile
- 13.2 Octapharma AG Mild Cognitive Impairment (MCI) Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status
- 13.4 Drug Overview

- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14 PARTNER THERAPEUTICS INC MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 14.1 Partner Therapeutics Inc Business Profile
- 14.2 Partner Therapeutics Inc Mild Cognitive Impairment (MCI) Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity
 - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 PFIZER INC MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 15.1 Pfizer Inc Business Profile
- 15.2 Pfizer Inc Mild Cognitive Impairment (MCI) Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator
 - 15.3.2 Collaborator/Co-Developer
 - 15.3.3 Route of Administration
 - 15.3.4 Orphan Drug/Fast Track/Special Designation
 - 15.3.5 Geography
 - 15.3.6 Type of Molecular Entity
 - 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16 PROTEKT THERAPEUTICS LTD MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 16.1 Protekt Therapeutics Ltd Business Profile
- 16.2 Protekt Therapeutics Ltd Mild Cognitive Impairment (MCI) Drug Details
- 16.3 Drug Snapshot
 - 16.3.1 Originator
 - 16.3.2 Collaborator/Co-Developer
 - 16.3.3 Route of Administration
 - 16.3.4 Orphan Drug/Fast Track/Special Designation
 - 16.3.5 Geography
 - 16.3.6 Type of Molecular Entity
 - 16.3.7 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17 SBI PHARMACEUTICALS CO LTD MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 17.1 SBI Pharmaceuticals Co Ltd Business Profile
- 17.2 SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment (MCI) Drug Details
- 17.3 Drug Snapshot
 - 17.3.1 Originator
 - 17.3.2 Collaborator/Co-Developer
 - 17.3.3 Route of Administration
 - 17.3.4 Orphan Drug/Fast Track/Special Designation
 - 17.3.5 Geography
 - 17.3.6 Type of Molecular Entity
 - 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18 THERAPIX BIOSCIENCES LTD MILD COGNITIVE IMPAIRMENT (MCI) PIPELINE DETAILS

- 18.1 Therapix Biosciences Ltd Business Profile
- 18.2 Therapix Biosciences Ltd Mild Cognitive Impairment (MCI) Drug Details
- 18.3 Drug Snapshot
 - 18.3.1 Originator
 - 18.3.2 Collaborator/Co-Developer
 - 18.3.3 Route of Administration
 - 18.3.4 Orphan Drug/Fast Track/Special Designation
 - 18.3.5 Geography
 - 18.3.6 Type of Molecular Entity
 - 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19. LATEST MILD COGNITIVE IMPAIRMENT (MCI) DRUG PIPELINE DEVELOPMENTS, 2019

20. APPENDIX

- 20.1 About Us
- 20.2 Sources and Methodology
- 20.3 Contact Information

I would like to order

Product name: 2019 Future of Mild Cognitive Impairment (MCI) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/274C794BF10EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/274C794BF10EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970